Figure 3.
Figure 3. The PI3 kinase/Akt/mTOR pathway is frequently activated in HRS cells. Pharmacologic inhibition of mTOR has produced clinical responses in patients with relapsed classical Hodgkin lymphoma (HL).

The PI3 kinase/Akt/mTOR pathway is frequently activated in HRS cells. Pharmacologic inhibition of mTOR has produced clinical responses in patients with relapsed classical Hodgkin lymphoma (HL).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal